InnoSer News: December 2024
Read more about our preclinical research and general drug development services and updates in our monthly LinkedIn newsletter.?Click and read below about some of our August's highlights across our therapeutic area expertise.
MDX Mouse Model
This month we’re highlighting one of the most commonly used mouse models to study Duchenne Muscular Dystrophy (DMD) – the MDX mouse model B10.mdx), and explore how our advanced services can support your efficacy studies in DMD.??Head over to our page to discover recommended motor function readouts to assess skeletal muscle strength and InnoSer's validation data, including skeletal muscle histopathology: https://www.innoserlaboratories.com/newsletter/mdx-mouse-model-validation-data/.
Pancreatic Cancer Awareness Month
Last month, November, represented Pancreatic Cancer Awareness Month; a time to focus on the challenges posed by one of the most aggressive and lethal cancer types. Pancreatic cancer accounts for approximately 3% of all diagnosed cancers in Europe, with pancreatic ductal adenocarcinoma (PDAC) being the most common subtype.??
At InnoSer, we recognize the complexity of finding a treatment for pancreatic cancer and offer a comprehensive suite of preclinical research tools tailored to accelerate your preclinical research efforts. Head over to our website to discover's InnoSer's available syngeneic, cell line-derived xenograft (CDX), and patient-derived xenograft (PDX) mouse models to study the efficacy of compounds targeting PDAC: https://www.innoserlaboratories.com/newsletter/pancreatic-cancer-pdx-models/.
Catch-up on Previous Blog Posts: